Kevin R. Lind
2022 - Longboard Pharmaceuticals
In 2022, Kevin R. Lind earned a total compensation of $1.5M as President and Chief Executive Officer at Longboard Pharmaceuticals, a 72% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $377,520 |
|---|---|
| Option Awards | $544,070 |
| Salary | $572,000 |
| Other | $12,325 |
| Total | $1,505,915 |
Lind received $572K in salary, accounting for 38% of the total pay in 2022.
Lind also received $377.5K in non-equity incentive plan, $544.1K in option awards and $12.3K in other compensation.
Rankings
In 2022, Kevin R. Lind's compensation ranked 2,219th out of 5,736 executives tracked by ExecPay. In other words, Lind earned more than 61.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,219 out of 5,736 | 61st |
Division Manufacturing | 1,204 out of 3,125 | 62nd |
Major group Chemicals And Allied Products | 527 out of 1,416 | 63rd |
Industry group Drugs | 485 out of 1,317 | 63rd |
Industry Pharmaceutical Preparations | 352 out of 963 | 63rd |
Source: SEC filing on April 11, 2023.
Lind's colleagues
We found two more compensation records of executives who worked with Kevin R. Lind at Longboard Pharmaceuticals in 2022.